Isocyclophosphamide
Central Nervous System Neoplasm
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01505569CT.gov Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | — | Completed | — | — | — |
NCT00788125CT.gov Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | — | Terminated | — | — | — |
NCT00551122CT.gov Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors | — | Unknown | — | — | — |
NCT00623077CT.gov MT2004-30: Tomotherapy for Solid Tumors | — | Terminated | — | — | — |
NCT00278278CT.gov Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas | — | Unknown | — | — | — |
NCT00003657CT.gov High-dose ICE With Amifostine | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Central Nervous System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Isocyclophosphamide (this asset) | Masonic Cancer Center, University of Minnesota | P3 | BBB · 72 |
| Procarbazine | Universitätsmedizin Mannheim | P3 | BBB |
| Vincristine Sulfate | Northwestern University | P3 | BBB |
| Irinotecan | EpicentRx, Inc. | P2 | BBB |
| Gefitinib | Memorial Sloan Kettering Cancer Center | P2 | BBB |
| Etoposide | NewLink Genetics Corporation | P3 | BBB |
| Carboplatin | OHSU Knight Cancer Institute | P3 | BBB |
| Nivestim | St. Jude Children's Research Hospital | P3 | BBB |
| Camustine | Lisata Therapeutics, Inc. | P3 | BBB |
+42 more in the Central Nervous System Neoplasm cohort
Other indications for Isocyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Angioimmunoblastic T-Cell Lymphoma | — | P4 | BBB · 76 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P4 | BBB · 76 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Isocyclophosphamide in Central Nervous System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/isocyclophosphamide-central-nervous-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →